Rheumatoid arthritis (RA) is a chronic autoimmune inflammation disorder, which mainly affects the articulations, leading them to progressive destruction. RA bear upon 0.5-1% of people in the developed world according to statistics drafted in 2015. The onset of symptoms often takes several weeks, leading to the appearance of warmness, redness, swelling and pain in affected juncture. Nowadays, the therapy to treat RA consists mainly in relieving the symptoms and slowing the evolution of the disease using analgesic, anti-inflammatory and disease-modifying anti-rheumatic drugs (DMARDs) drugs. Nevertheless, there is still no therapy that completely blocks the progression of the disease. A new treatment currently in phase of in vivo testing, achieve the goal of halting the development of RA, blocking the destruction of articulations.